Kyowa Kirin licenses in transdermal granisetron for four Asian markets
This article was originally published in Scrip
Kyowa Hakko Kirin is strengthening its oncology business in Asia through the acquisition of exclusive marketing rights to a transdermal patch formulation of granisetron in selected markets.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.